-
Lanopepden
- names:
N-[(2R)-2-(cyclopentylmethyl)-3-(2-{5-fluoro- 6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]- 2-methylpyrimidin-4-yl}hydrazin-1-yl)-3-oxopropyl]- N-hydroxyformamide
- CAS号:
1152107-25-9
MDL Number: - MF(分子式): C22H34FN7O4 MW(分子量): 479.56
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|
| 中文别名 | Lanopepden |
| 英文别名 | GSK-1322322; GSK1322322; GSK 1322322; GSK-1322322B; GSK-322; GSK322; GSK 322; GSK-1322322J; Lanopepden; GSK 1322322B |
| CAS号 | 1152107-25-9 |
| Inchi | InChI=1S/C22H34FN7O4/c1-15-24-20(19(23)21(25-15)29-7-6-28-8-9-34-13-18(28)12-29)26-27-22(32)17(11-30(33)14-31)10-16-4-2-3-5-16/h14,16-18,33H,2-13H2,1H3,(H,27,32)(H,24,25,26)/t17-,18+/m1/s1 |
| InchiKey | SWHNZGMQMGFQGW-MSOLQXFVSA-N |
| 分子式 Formula | C22H34FN7O4 |
| 分子量 Molecular Weight | 479.56 |
| 溶解度Solubility | |
| 性状 | Solid powder |
| 储藏条件 Storage conditions | Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years). |
| 产品说明 | Lanopepden(CAS:1152107-25-9 ):仅限应用于工业或者科学研究过程中非医疗目的,不应用于人类或动物的临床诊断以及治过程疗,该产品非药用,非食用。 |
| Introduction | Lanopepden, also known as GSK-1322322 or GSK-322, is a potent and selective peptide deformylase inhibitor with good in vitro activity against bacteria associated with community-acquired pneumonia and skin infections. GSK1322322 had bactericidal activity against S. pneumoniae, H. influenzae, S. pyogenes, and S. aureus, demonstrating a ≥ 3-log(10) decrease in the number of CFU/ml at 4× MIC within 24 h in 29 of the 33 strains tested. GSK1322322 represents a valuable alternative therapy for the treatment of infectious diseases caused by drug-resistant pathogens. |
| Application1 | |
| Application2 | |
| Application3 |
| [1]Hoover J, Lewandowski T, Straub RJ, Novick SJ, DeMarsh P, Aubart K, Rittenhouse S, Zalacain M. Pharmacokinetics/Pharmacodynamics (PK/PD) of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in rodent models of infection. Antimicrob Agents Chemother. 2015 Oct 19. pii: AAC.01842-15. [Epub ahead of print] PubMed PMID: 26482300. |
| [2]Peyrusson F, Butler D, Tulkens PM, Van Bambeke F. Cellular pharmacokinetics and intracellular activity of the novel peptide deformylase inhibitor GSK1322322 against Staphylococcus aureus laboratory and clinical strains with various resistance phenotypes: studies with human THP-1 monocytes and J774 murine macrophages. Antimicrob Agents Chemother. 2015 Sep;59(9):5747-60. doi: 10.1128/AAC.00827-15. Epub 2015 Jul 13. PubMed PMID: 26169402; PubMed Central PMCID: PMC4538490. |
| [3] Naderer O, Jones LS, Zhu J, Coffin MD, Kurtinecz M, Dumont E. The Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GSK1322322 in Healthy Volunteers. Clin Pharmacol Drug Dev. 2015 Jan;4(1):49-55. Epub 2014 Oct 27. PubMed PMID: 26097792; PubMed Central PMCID: PMC4467258. |
| [4] Min S, Ingraham K, Huang J, McCloskey L, Rilling S, Windau A, Pizzollo J, Butler D, Aubart K, Miller LA, Zalacain M, Holmes DJ, O'Dwyer K. Frequency of Spontaneous Resistance to Peptide Deformylase Inhibitor GSK1322322 in Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2015 Aug;59(8):4644-52. doi: 10.1128/AAC.00484-15. Epub 2015 May 26. PubMed PMID: 26014938; PubMed Central PMCID: PMC4505285. |
| [5] Arat S, Spivak A, Van Horn S, Thomas E, Traini C, Sathe G, Livi GP, Ingraham K, Jones L, Aubart K, Holmes DJ, Naderer O, Brown JR. Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase. Antimicrob Agents Chemother. 2015 Feb;59(2):1182-92. doi: 10.1128/AAC.04506-14. Epub 2014 Dec 8. PubMed PMID: 25487798; PubMed Central PMCID: PMC4335841. |
6: Dubois J, Dubois M, Martel JF, Aubart K, Butler D. In vitro and intracellular activities of peptide deformylase inhibitor GSK1322322 against Legionella pneumophila isolates. Antimicrob Agents Chemother. 2015 Jan;59(1):707-10. doi: 10.1128/AAC.04006-14. Epub 2014 Oct 27. PubMed PMID: 25348534; PubMed Central PMCID: PMC4291349.7: Corey R, Naderer OJ, O'Riordan WD, Dumont E, Jones LS, Kurtinecz M, Zhu JZ. Safety, tolerability, and efficacy of GSK1322322 in the treatment of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2014 Nov;58(11):6518-27. doi: 10.1128/AAC.03360-14. Epub 2014 Aug 18. PubMed PMID: 25136015; PubMed Central PMCID: PMC4249383.8: Mamaril-Fishman D, Zhu J, Lin M, Felgate C, Jones L, Stump P, Pierre E, Bowen C, Naderer O, Dumont E, Patel P, Gorycki PD, Wen B, Chen L, Deng Y. Investigation of metabolism and disposition of GSK1322322, a peptidase deformylase inhibitor, in healthy humans using the entero-test for biliary sampling. Drug Metab Dispos. 2014 Aug;42(8):1314-25. doi: 10.1124/dmd.114.058420. Epub 2014 May 28. PubMed PMID: 24872378.9: Naderer OJ, Rodvold KA, Jones LS, Zhu JZ, Bowen CL, Chen L, Dumont E. Penetration of GSK1322322 into epithelial lining fluid and alveolar macrophages as determined by bronchoalveolar lavage. Antimicrob Agents Chemother. 2014;58(1):419-23. doi: 10.1128/AAC.01836-13. Epub 2013 Nov 4. PubMed PMID: 24189245; PubMed Central PMCID: PMC3910803.10: Butler D, Chen D, O'Dwyer K, Lewandowski T, Aubart K, Zalacain M. Potent sub-MIC effect of GSK1322322 and other peptide deformylase inhibitors on in vitro growth of Staphylococcus aureus. Antimicrob Agents Chemother. 2014;58(1):290-6. doi: 10.1128/AAC.01292-13. Epub 2013 Oct 28. PubMed PMID: 24165188; PubMed Central PMCID: PMC3910740.1
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


